Jefferies resumed coverage on Inovio Pharma with a new price target

Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) Resolved previously announced manufacturing issue concerning the single-use array component of the CELLECTRA device and completed drafting of all non-device BLA modules On track to begin rolling submission of BLA in mid-2025 and to request priority review with goal of completing the submission in the second half of 2025 and receiving acceptance of the submission by end of the yearAnnounced durability data from retrospective study showing that 50% of patients achieved a Complete Response in the second 12-month period (year 2) with 86

Long-lasting in vivo antibody production: DMAb levels remained stable for 72 weeks in all participants (n=24) who have reached that timepointNo anti-drug antibodies (ADA): no immune rejection of the DMAbs was detected across ~1,000 blood samples, unlike other gene-based antibody delivery approaches where ADA formation has been a challengeWell-tolerated: most common side effects were mild, temporary injection site reactions such as pain and redness; no serious adverse events (SAEs) related to study drugEffective target binding: expressed DMAbs successfully bound to the SARS-CoV-2 Spike protein receptor-binding domain (RBD), confirming functional activity through week 72PLYMOUTH MEETING, Pa.,

PLYMOUTH MEETING, Pa., March 12, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that fourth quarter and year-end 2024 financial results will be released after the market close on March 18, 2025. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update. The live webcast will be available online

Stephens initiated coverage of Inovio Pharma with a rating of Overweight and set a new price target of $20.00

Oppenheimer upgraded Inovio Pharma from Perform to Outperform and set a new price target of $4.00

Maxim Group downgraded Inovio Pharma from Buy to Hold

4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)

4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)

4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)

8-K - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)

10-K - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)

SCHEDULE 13G - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)

PLYMOUTH MEETING, Pa., Jan. 9, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today highlighted anticipated milestones for 2025 and key accomplishments from 2024 in advance of upcoming investor meetings. "Based on the progress achieved in 2024, we anticipate 2025 to be a transformational year for INOVIO as we move closer to our goal of becoming a commercial-stage company providing a breakthrough therapy for pati

Mr. Egge brings over 25 years of biopharmaceutical experience building commercial organizations and successfully launching novel therapeutic products INOVIO poised to become a commercial-stage company with plans to submit a Biologics License Application for INO-3107 in second half of 2024 under U.S. Food and Drug Administration's Accelerated Approval Pathway PLYMOUTH MEETING, Pa., July 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the appointment of Steven Egge as Chief Commercial Officer. Mr. Egge will le

PLYMOUTH MEETING, Pa., June 27, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced the appointment of Dr. Michael Sumner, MB BS, MBA, as Chief Medical Officer (CMO). Dr. Sumner will oversee INOVIO's clinical-stage pipeline of DNA medicines, global clinical development, clinical operations and biostatistics efforts, as well as regulatory affairs, pharmacovigilance and medical affairs. He will serve on the company's executive leadership team and will report to INOVIO's President and Chief Executive Offic

Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) Resolved previously announced manufacturing issue concerning the single-use array component of the CELLECTRA device and completed drafting of all non-device BLA modules On track to begin rolling submission of BLA in mid-2025 and to request priority review with goal of completing the submission in the second half of 2025 and receiving acceptance of the submission by end of the yearAnnounced durability data from retrospective study showing that 50% of patients achieved a Complete Response in the second 12-month period (year 2) with 86

PLYMOUTH MEETING, Pa., March 12, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that fourth quarter and year-end 2024 financial results will be released after the market close on March 18, 2025. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update. The live webcast will be available online

New immunology data for INO-3107 supporting proposed mechanism of action presented at several recent conferences Data showed ability of INO-3107 to induce an antigen-specific cytotoxic T cell response against HPV-6 and HPV-11 and drive recruitment of T cells into airway tissues and papillomaData showed INO-3107 induced expansion of new clonal T cells that infiltrate airway tissues and correspond with reduction of surgeries for RRP patients observed in Phase 1/2 trialContinued progress on preparing regulatory submissions for INO-3107All non-device BLA modules on track for completion by end of 2024 BLA submission remains targeted for mid-2025PLYMOUTH MEETING, Pa., Nov. 14, 2024 /PRNewswire/ --

SC 13G - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)

SC 13G/A - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)

SC 13G/A - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)